Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Alta Equipment Group Announces Third Quarter 2026 Financial Results (GlobeNewswire EN) +++ ALTA EQUIPMENT Aktie -3,60%

HALOZYME Aktie

 >HALOZYME Aktienkurs 
91.46 EUR    -1.6%    (TradegateBSX)
Ask: 92.02 EUR / 110 Stück
Bid: 91.56 EUR / 110 Stück
Tagesumsatz: 756 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
HALOZYME Aktie über LYNX handeln
>HALOZYME Performance
1 Woche: -20,8%
1 Monat: -5,3%
3 Monate: +25,7%
6 Monate: +66,5%
1 Jahr: +57,6%
laufendes Jahr: +59,1%
>HALOZYME Aktie
Name:  HALOZYME THERAPEUTICS
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US40637H1095 / A0DLHS
Symbol/ Ticker:  RV7 (Frankfurt) / HALO (NASDAQ)
Kürzel:  FRA:RV7, ETR:RV7, RV7:GR, NASDAQ:HALO
Index:  -
Webseite:  https://halozyme.com/
Profil:  Halozyme Therapeutics Inc. is a biopharmaceutical technology company focused on drug delivery solutions and specialty medicines. Its core platform, ENHANZE, uses the proprietary enzyme rHuPH20 to help enable subcutaneous delivery of injectable therap..
>Volltext..
Marktkapitalisierung:  13279.23 Mio. EUR
Unternehmenswert:  14969.77 Mio. EUR
Umsatz:  1493.45 Mio. EUR
EBITDA:  950.95 Mio. EUR
Nettogewinn:  371.26 Mio. EUR
Gewinn je Aktie:  3.16 EUR
Schulden:  1926.94 Mio. EUR
Liquide Mittel:  146.44 Mio. EUR
Operativer Cashflow:  734.81 Mio. EUR
Bargeldquote:  0.67
Umsatzwachstum:  45.59%
Gewinnwachstum:  -23.45%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  HALOZYME
Letzte Datenerhebung:  09.11.26
>HALOZYME Kennzahlen
Aktien/ Unternehmen:
Aktien: 113.5 Mio. St.
Frei handelbar: 98.92%
Rückkaufquote: 2.34%
Mitarbeiter: 423
Umsatz/Mitarb.: 2.96 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 4.2%
Bewertung:
KGV: 31.96
KGV lG: 12.19
KUV: 9.48
KBV: 84.98
PEG-Ratio: -
EV/EBITDA: 15.74
Rentabilität:
Bruttomarge: 76.4%
Gewinnmarge: 24.86%
Operative Marge: 56.77%
Managementeffizenz:
Gesamtkaprendite: 17.86%
Eigenkaprendite: 173.67%
>HALOZYME Peer Group
Gesundheit, Onkologie/ Krebs- Behandlung
 
06.11.26 - 19:45
Halozyme Stock Down Despite Q3 Earnings and Revenue Beat (Zacks)
 
HALO's Q3 earnings & revenues beat estimates, driven by higher royalties and product sales. The company raises its 2026 outlook, yet shares fall in after-hours....
06.11.26 - 17:30
HALO Q3 Earnings Call Highlights Royalty Growth and Patent Dispute (Zacks)
 
Halozyme lifts its 2026 outlook after a 44% royalty surge, as ENHANZE expansion, Hypercon trials and a Merck patent dispute draw investors' focus....
06.11.26 - 17:21
Halozyme dips as Leerink downgrades on “marginal” Q3 upside (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
06.11.26 - 16:06
Halozyme Reaffirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Medicare Drug Price Negotiation Program Final Rule for IPAY 2029 (PR Newswire)
 
SAN DIEGO, Nov. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact based on its analysis of the final rule for the Medicare Drug Price Negotiation Program......
06.11.26 - 16:00
U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme′s ENHANZE® Technology for the Treatment of Advanced Head and Neck Cancer (PR Newswire)
 
Approval extends RYBREVANT FASPRO's well-established, dual-targeted benefit beyond lung cancer SAN DIEGO, Nov. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) (Halozyme) today announced that Johnson & Johnson was granted accelerated approval from the U.S. Food and Drug......
06.11.26 - 10:54
Halozyme Therapeutics unter Druck: Enttäuschende Prognoseanhebung lässt Aktie vorbörslich einbrechen (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
06.11.26 - 08:36
Halozyme (HALO) Q3 2026 Earnings Call Transcript (Fool)
 
Merck patent setbacks in the U.S. cloud an otherwise strong quarter for royalties....
06.11.26 - 03:00
Halozyme expects $1.86B-$1.925B 2026 revenue while raising non-GAAP EPS to $8.75-$9.05 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
06.11.26 - 01:45
Compared to Estimates, Halozyme Therapeutics (HALO) Q3 Earnings: A Look at Key Metrics (Zacks)
 
The headline numbers for Halozyme Therapeutics (HALO) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals....
06.11.26 - 01:01
Halozyme Therapeutics (HALO) Tops Q3 Earnings and Revenue Estimates (Zacks)
 
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of +4.37% and +2.27%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?...
06.11.26 - 00:06
Halozyme falls 6% as raised guidance fails to impress investors (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
05.11.26 - 22:12
Halozyme Therapeutics Non-GAAP EPS of $2.39 beats by $0.03, revenue of $493M beats by $1.44M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
05.11.26 - 22:09
HALOZYME REPORTS THIRD QUARTER 2026 RESULTS AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE (PR Newswire)
 
Total Revenue Increased 39% YOY to $493 million Royalty Revenue Increased 44% YOY to $341 million Raising 2026 Financial Guidance Ranges: Total Revenue of $1.860 - $1.925 billion, YOY Growth of 33% - 38% Royalty Revenue of $1.235 - $1.255 billion, YOY Growth of 42% - 45% Adjusted EBITDA......
29.10.26 - 16:30
Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
 
Halozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....
22.10.26 - 14:33
Halozyme to Report Third Quarter 2026 Financial and Operating Results (PR Newswire)
 
SAN DIEGO, Oct. 22, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will release its third quarter 2026 financial and operating results on Thursday, November 5, 2026, following the close of trading. Halozyme will host a conference call on......
22.10.26 - 14:30
The Zacks Analyst Blog Highlights Chord Energy, Halozyme, Sezzle, SanDisk and Teradyne (Zacks)
 
CHRD, HALO, SEZL, SNDK and TER boast strong margins and growth prospects, with earnings catalysts ahead as October 2026 results roll in....
15.10.26 - 16:00
Here′s How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today (Zacks)
 
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards....
14.10.26 - 20:30
3 Reasons Why Growth Investors Shouldn′t Overlook Halozyme Therapeutics (HALO) (Zacks)
 
Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes....
13.10.26 - 19:45
Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report? (Zacks)
 
Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report....
09.10.26 - 07:01
Insiderhandel: PRESIDENT AND CEO verkauft Aktien von Halozyme Therapeutics im Wert von 2187910 USD (Insiderkauf)
 
Torley, Helen - Vorstand - Tag der Transaktion: 2026-10-08...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Es gibt Tage, da geht alles schief. Umso schöner ist es, wenn man weiß, daß man bedingungslos geliebt wird. - James Morgan
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!